New York State Common Retirement Fund Decreases Position in Curis, Inc. (CRIS)
New York State Common Retirement Fund reduced its stake in shares of Curis, Inc. (NASDAQ:CRIS) by 0.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 101,500 shares of the biotechnology company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned approximately 0.07% of Curis worth $192,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after purchasing an additional 304,268 shares during the period. Geode Capital Management LLC lifted its stake in Curis by 8.3% in the first quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock valued at $2,553,000 after acquiring an additional 70,139 shares during the last quarter. Rhumbline Advisers lifted its stake in Curis by 1.9% in the second quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 2,340 shares during the last quarter. BB&T Securities LLC acquired a new stake in Curis in the second quarter valued at approximately $179,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in Curis by 9.3% in the first quarter. Metropolitan Life Insurance Co. NY now owns 90,156 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 7,638 shares during the last quarter. Institutional investors and hedge funds own 46.88% of the company’s stock.
A number of analysts have recently weighed in on CRIS shares. Guggenheim started coverage on shares of Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $6.50.
Shares of Curis, Inc. (CRIS) opened at $0.90 on Friday. Curis, Inc. has a one year low of $0.86 and a one year high of $3.48. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.
Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The company had revenue of $2.44 million for the quarter, compared to the consensus estimate of $2.19 million. During the same period last year, the firm posted ($0.21) EPS. The company’s revenue was up 38.6% compared to the same quarter last year. sell-side analysts forecast that Curis, Inc. will post -0.41 EPS for the current fiscal year.
In other Curis news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $1.06 per share, with a total value of $53,000.00. Following the acquisition, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 4.07% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “New York State Common Retirement Fund Decreases Position in Curis, Inc. (CRIS)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-decreases-position-in-curis-inc-cris/1725136.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.